About Us

We address the underlying causes of ophthalmic diseases

Enhancing Lives & Better Vision

Okogen is an ophthalmic specialty pharmaceutical company focused on developing innovative therapies to treat adenoviral conjunctivitis.

We believe in addressing both the underlying cause of the disease and treating the associated symptoms. 

Our lead product candidate, OKG-0502, is being developed to treat adenoviral conjunctivitis (also known as pink eye), a viral infection that affects approximately 30 million people worldwide each year and for which there are no approved therapies.

Meet the Team

Management & Executive Board Directors

Brian M. Strem, PhD

Chief Executive Officer
Read More

Eric J. Daniels, MD, MBA

Chief Operating Officer
Read More

Non-Executive
Board Directors

Chris Smith, PhD, MBA

Read More

Leighton Read, MD

Read More

Quinton Oswald

Read More

Scientific & Medical Advisory Board

Francis Mah, MD

Jay Pepose, MD, PhD

John Sheppard, MD

Russel Van Gelder, MD, PhD

Stephanie Watson, MD